<unk> , sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Common side effects include diarrhea, headache, and high blood pressure. Serious side effects may include infections, cancer, and pulmonary embolism. In 2019, the safety committee of the European Medicines Agency began a review of<unk>  and recommended that doctors temporarily not prescribe the 10 mg twice-daily dose to people at high risk for pulmonary embolism. The U.S. Food and Drug Administration (FDA) also released warnings about the risk of blood clots. An important side effect of Jakinibs is serious bacterial, mycobacterial, fungal and viral infections. In the phase 3 trials of<unk>  among opportunistic infections, pulmonary tuberculosis (TB) was reported in 3 cases all of which were initially negative upon screening for TB. It is in the janus kinase (JAK) inhibitor class, discovered and developed by the National Institutes of Health and Pfizer.<unk>  is a small molecule, not a biologic. As of June 2021,<unk>  is available as a generic medicine in the US.
Tofacitinib
Ocrelizumab
Belatacept
Etanercept
Ibalizumab
Sarilumab
Theralizumab
Atezolizumab